Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.

J Clin Med · 2026 · PMC13026821 · PMID 41899095

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Notably, patients with signaling mutations, contributing to resistance, appeared to benefit from the triple regimen, although this result did not reach statistical significance [ 228 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.